Top ▲

Acne vulgaris

Disease ID:1255
Name:Acne vulgaris
Associated with:0 target
1 immuno-relevant ligand
adult acne
Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous glands. Keratinocytes and sebocytes in infected microcomedo lesions produce proinflammatory chemokines and cytokines that attract lymphocytes and T-helper cells, which causes a localised inflammatory response.
Database Links
Disease Ontology: DOID:6543
OMIM: 604324


No target related data available for Acne vulgaris


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Phase 3 clinical candidate for acne vulgaris- see NCT02189629. Retinoid drugs reduce the proinflammatory factors and disrupt the immunoinflammatory cascade associated with acne vulgaris.
Clinical Use: Trifarotene (CD5789) has completed Phase 3 clinical trial in patients with acne vulgaris, including the long term safety study NCT02189629 [1]. FDA approval for clinical use in patients with acne was granted in October 2019 (for Aklief®, a 0.005% topically applied cream). | View clinical data
Bioactivity Comments: The high metabolic instability of trifarotene (CD5789) suggests that it will exhibit limited systemic exposure when used as a topical agent. | View biological activity


Show »

1. Blume-Peytavi U, Fowler J, Kemény L, Draelos Z, Cook-Bolden F, Dirschka T, Eichenfield L, Graeber M, Ahmad F, Alió Saenz A et al.. (2020) Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol, 34 (1): 166-173. [PMID:31306527]